Wells Fargo raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps an Overweight rating on the shares following the disclosure of the company’s involvement with Ralinepag DPI, and ahead of Afrezza and Furoscix PDUFAs. The firm believes there are now multiple avenues for revenue growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind reports Q1 EPS (2c), consensus 1c
- MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
- MNKD Earnings this Week: How Will it Perform?
- MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
- MannKind price target lowered to $8 from $10 at Mizuho